SEARCH

SEARCH BY CITATION

References

  • 1
    Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1, oxidative stress and disease. Antioxid Redox Signal 2011; 14: 131535.
  • 2
    Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 13962.
  • 3
    Yanai H, Ban T, Taniguchi T. HMGB proteins in nucleic acid-mediated innate immune responses. J Intern Med 2011; 270.
  • 4
    Urbonaviciute V, Voll RE. HMGB1 in SLE. J Intern Med 2011; 270.
  • 5
    Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. IL-1R/TLR signaling in epilepsy: the focus on IL-1beta and HMGB1. J Intern Med 2011; 270.
  • 6
    Yanai H, Ban T, Wang Z et al. HMGB proteins function as universal sentinels for nucleic acid-mediated innate immune responses. Nature 2009; 462: 99103.
  • 7
    Ivanov S, Dragoi AM, Wang X et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110: 197081.
  • 8
    Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007; 16: 794802.
  • 9
    Urbonaviciute V, Furnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 300718.
  • 10
    Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 7278.
  • 11
    Bruchfeld A, Qureshi AR, Lindholm B et al. High Mobility Group Box Protein-1 correlates with renal function in chronickidney disease. Mol Med 2008; 14: 10915.
  • 12
    Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010; 9: 6615.
  • 13
    Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37: 76675.
  • 14
    Ma CY, Jiao YL, Zhang J et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus. Rheumatol Int 2010 (Epub ahead of print).
  • 15
    Urbonaviciute V, Furnrohr BG, Weber C et al. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007; 81: 6774.
  • 16
    Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R71.
  • 17
    Banerjee S, Friggeri A, Liu G, Abraham E. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol 2010; 88: 9739.
  • 18
    Friggeri A, Yang Y, Banerjee S, Park YJ, Liu G, Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the αvβ3-integrin. Am J Physiol Cell Physiol 2010; 299: 126776.
  • 19
    Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 2132.
  • 20
    Yang H, Hreggvidsdottir HS, Palmblad K et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010; 107: 119427.
  • 21
    Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med 2010; 16: 47990.
  • 22
    Hreggvidsdottir H. Dual cytokine inducing properties of HMGB1. Stockholm: Karolinska Institutet, PhD Thesis, 2011; pp. 119.
  • 23
    Vezzani A, Conti M, De Luigi A et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 1999; 19: 505465.
  • 24
    Vezzani A, Moneta D, Conti M et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 2000; 97: 115349.
  • 25
    Maroso M, Balosso S, Ravizza T et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 4139.
  • 26
    Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008; 180: 25317.
  • 27
    Hreggvidsdottir HS, Ostberg T, Wähämaa H et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86: 65562.
  • 28
    Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991; 266: 167229.